Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03896737
Title Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network
Indications

multiple myeloma

Therapies

Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone

Ixazomib

Bortezomib + Dexamethasone + Thalidomide

Daratumumab + Ixazomib

Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.